Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

[1]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[2]  C. Denkert,et al.  MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer , 2014, BMC Cancer.

[3]  R. Bernards,et al.  Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway , 2014, Proceedings of the National Academy of Sciences.

[4]  A. Adjei,et al.  The clinical development of MEK inhibitors , 2014, Nature Reviews Clinical Oncology.

[5]  J. M. Jerez,et al.  Concurrent radiotherapy plus epidermal growth factor receptor inhibitors in patients with human papillomavirus-related head and neck cancer , 2014, Clinical and Translational Oncology.

[6]  J. M. Jerez,et al.  Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer , 2013, BMC Cancer.

[7]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[8]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .

[9]  R. Seger,et al.  The MAPK cascades: signaling components, nuclear roles and mechanisms of nuclear translocation. , 2011, Biochimica et biophysica acta.

[10]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  M. Mclaughlin,et al.  Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression , 2011, Cell.

[12]  S. Lippman,et al.  Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC) , 2010, Head & neck oncology.

[13]  Rony Seger,et al.  The subcellular localization of MEK and ERK—A novel nuclear translocation signal (NTS) paves a way to the nucleus , 2010, Molecular and Cellular Endocrinology.

[14]  Paul Timpson,et al.  Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[15]  S. Cook,et al.  Tumour cell survival signalling by the ERK1/2 pathway , 2009, Cell Death and Differentiation.

[16]  A. Russo,et al.  HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988-2007). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Seger,et al.  Identification and characterization of a general nuclear translocation signal in signaling proteins. , 2008, Molecular cell.

[18]  A. Garden,et al.  Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  J. Bussink,et al.  Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. , 2008, The Lancet. Oncology.

[20]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[21]  Rony Seger,et al.  The MEK/ERK cascade: from signaling specificity to diverse functions. , 2007, Biochimica et biophysica acta.

[22]  R. Seger,et al.  The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.

[23]  M. Barbacid,et al.  RAS oncogenes: the first 30 years , 2003, Nature Reviews Cancer.

[24]  A. Fortin,et al.  p53 and Ki‐67 as markers of radioresistance in head and neck carcinoma , 2002, Cancer.

[25]  Wolzt,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2003, The Journal of the American College of Dentists.

[26]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[27]  H. Rubinfeld,et al.  Nuclear translocation of mitogen-activated protein kinase kinase (MEK1) in response to mitogenic stimulation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Elizabeth Yang,et al.  Serine Phosphorylation of Death Agonist BAD in Response to Survival Factor Results in Binding to 14-3-3 Not BCL-XL , 1996, Cell.

[29]  C. Thompson,et al.  Apoptosis Meets Signal Transduction: Elimination of a BAD Influence , 1996, Cell.

[30]  E. Krebs,et al.  The MAPK signaling cascade , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[31]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2004, Journal international de bioethique = International journal of bioethics.

[32]  J. Levine,et al.  Surfing the p53 network , 2000, Nature.